The DOI matches its Crossref record; 70 of the 74 references it cites were found in a registry or an index; 14 of the 43 sources its claims cite were checked for support.
Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21
Open accessAbstract
Lung cancer is the leading cause of cancer-related deaths in the world, and non-small-cell lung cancer (NSCLC) accounts for 80% of cases. MicroRNA-21 (miR-21) expression is increased and predicts poor survival in NSCLC. Although miR-21 function has been studied in vitro with cancer cell lines, the role of miR-21 in tumor development in vivo is unknown. We utilize transgenic mice with loss-of-function and gain-of-function miR-21 alleles combined with a model of NSCLC to determine the role of miR-21 in lung cancer. We show that overexpression of miR-21 enhances tumorigenesis and that genetic deletion of miR-21 partially protects against tumor formation. MiR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In a K-rasLA2 mouse model of NSCLC, miR-21 overexpression increased lung tumor number/area and proliferation, while miR-21 deletion reduced tumor burden and sensitized transformed MEFs to doxorubicin-induced apoptosis. miR-21 acts as a tumor promoter by repressing Ras/MEK/ERK negative regulators (Spry1, Spry2, Btg2, Pdcd4) and pro-apoptotic genes (Apaf1, Faslg, Pdcd4, RhoB).
Key findings
- CAG-miR-21;K-rasLA2 mice overexpressing miR-21 4–6 fold had significantly more gross lung tumors at 18 weeks and increased microscopic tumor number and total tumor area versus K-rasLA2 littermates; tumors showed increased proliferation, but survival did not differ, possibly due to decreased thymic tumor incidence.
- miR-21−/−;K-rasLA2 mice had significantly fewer surface lung tumors at 20 weeks and decreased total tumor area; no adenocarcinomas were noted in any of 14 miR-21−/−/K-rasLA2 animals evaluated, and miR-21 deletion did not alter Ki67 proliferation.
- miR-21 overexpression alone was not sufficient for tumorigenesis: CAG-miR-21 mice without K-rasLA2 (n = 39) followed up to 555 days showed no tumors.
- Reporter assays showed 13 of 24 putative mouse miR-21 target 3′UTRs were repressed by miR-21, with mutation of the miR-21 site abrogating repression in 11; in tumors, miR-21 overexpression decreased Spry1, Spry2, Btg2, Pdcd4, Apaf1, Faslg, and RhoB and increased ERK phosphorylation. K-ras activation increased miR-21 expression 4-fold; miR-21−/− MEFs formed fewer soft agar colonies and smaller xenograft tumors and showed increased doxorubicin-induced apoptosis.
Methods
- Generated conditional CAG-miR-21 overexpressing and miR-21−/− mice, crossed to the K-rasLA2 NSCLC model; comparisons were to littermate controls, with tumor burden assessed by H&E/ImageJ, proliferation by Ki67, and apoptosis by TUNEL.
- MEFs from wild-type and miR-21−/− mice were immortalized with SV40 large T/small t and transformed with H-rasG12V; assays included soft agar, xenografts, doxorubicin treatment (100 nM–10 μM for 12 h), and TUNEL (1 μM for 12 h).
- Luciferase reporter assays tested 24 putative miR-21 target 3′UTRs; Western blots were performed on micro-dissected tumors; statistics used two-tailed unpaired Student’s t-test with p < 0.05 considered significant.
Limitations
- No formal limitations section is present; the authors state miR-21 overexpression alone was not sufficient for tumorigenesis and that tumors arising after miR-21 deletion may have developed escape mechanisms, possibly explaining latency.
- The text notes miR-21 deletion did not alter apoptosis in lung lesions, suggesting those tumors escaped miR-21 regulatory effects; no adenocarcinomas were observed in 14 miR-21−/−;K-rasLA2 animals, a limited sample for that endpoint.
- Evident from the text: all mice used were of mixed genetic backgrounds, and findings are from a mouse K-rasLA2 model and transformed MEFs, so human NSCLC causality and therapeutic implications remain to be tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 of 43 cited sources checked · 6 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Four of the validated miR-21 target genes are known negative regulators of the Ras/MEK/ERK pathway: sprouty 1 (Spry1), sprouty 2 (Spry2), B-cell translocation gene 2 (Btg2), and programmed cell death 4 (Pdcd4).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
What the sources say
- Partly supportedcites Casci et al., 1999 sourceExperimental — accuracy not yet measured
The Discussion identifies Drosophila Sprouty as an inhibitor of Ras/MAP kinase signaling. The paper predicts that mammalian Sprouty homologs may have the same function, but does not establish it for Spry1 or Spry2 specifically. It does not address Btg2, Pdcd4, or whether these genes are validated miR-21 targets. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites Hanafusa et al., 2002 source
- Not matchedcites Lo et al., 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Oncogenic Ras activation has been shown to increase the expression of Spry2, providing feedback inhibition of Ras activation (Shaw et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Partly supportedcites Shaw et al., 2007 sourceExperimental — accuracy not yet measured
In “Negative feedback signaling in development” (page not available), the paper reports that oncogenic K-ras up-regulates Spry-2 and that Spry-2 inhibits MAPK activation. It does not establish that Spry-2 inhibits activation of Ras itself; it describes possible effects at different points in the Ras/MAPK pathway, including downstream of activated K-ras. (LLM, conf=0.86)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that over-expression of miR-21 enhances tumorigenesis and genetic deletion of miR-21 partially protects against tumor formation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that over-expression of miR-21 enhances tumorigenesis and genetic deletion of miR-21 partially protects against tumor formation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“K-ras activation in the tumors of K-rasLA2 mice increased miR-21 expression 4-fold similar to the expression level in the CAG-miR-21 transgenic mouse lung.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total tumor area as a proportion of total lung area was significantly decreased with miR-21 deletion (Figure 2D).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 over-expression in CAG-miR-21;K-rasLA2 mutant tumors decreases Spry1, Spry2, and Btg2 protein expression compared to K-rasLA2 tumors (Figure 4C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This is may be explained by a decreased incidence of thymic tumors in CAG-miR-21;K-rasLA2 mutant mice compared to K-rasLA2 controls (Figure 1I), thus contributing to the enhanced survival.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no difference in proliferation between the miR-21−/− and wild type MEFs (Figure S2C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses Ras-driven transformation In vitro
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total tumor area as a proportion of total lung area was significantly increased with miR-21 over-expression (Figure 1E).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 25
- It may state two separate claims as one. 35
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, miR-21 expression levels have proven useful prognostic markers in non-small cell lung cancer (Markou et al., 2008; Yanaihara et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Supportedcites Markou et al., 2008 source
The discussion reports that mature miR-21 overexpression in NSCLC was associated with lung-cancer death and was an independent prognostic factor in multivariate analysis. The authors caution that the small number of events requires further confirmation, so the finding should not be read as a validated clinical test. (LLM, conf=0.88)
- Partly supportedcites Yanaihara et al., 2006 sourceExperimental — accuracy not yet measured
The Results report that high hsa-mir-21 expression was associated with significantly worse survival in lung adenocarcinoma patients. They do not establish miR-21 as a validated prognostic marker across non-small cell lung cancer: the reported prognostic validation focused on other miRNAs. (LLM, conf=0.88)
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The level of miR-21 expression in sputum distinguishes NSCLC patients from cancer-free controls with a greater sensitivity than conventional cytology (Xie et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Supportedcites Xie et al., 2009 source
The Results section, under “Comparison of cytology and measurement of altered miRNA expression in sputum,” reports 69.66% sensitivity for sputum miR-21 measurement versus 47.82% for conventional sputum cytology. The study examined sputum from 23 NSCLC patients and 17 cancer-free subjects, matching the claimed comparison. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several components of the PI3K pathway, including PTEN and PIK3R1, have been suggested as miR-21 target genes (Meng et al., 2007); however, miR-21 over-expression did not alter PTEN and PIK3R1 protein expression or Akt phosphorylation (Figure S3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
What the sources say
- Partly supportedcites Meng et al., 2007 sourceExperimental — accuracy not yet measured
The Results identify PTEN as a miR-21 target, and the Discussion places PTEN in the PI3K pathway. The passages do not identify PIK3R1 as a miR-21 target. The statement that over-expression did not alter protein expression or Akt phosphorylation is attributed to the citing paper’s Figure S3B, not to Meng et al. (LLM, conf=0.87)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Targeted deletion of miR-21 in RKO and DLD1 colon cancer cells revealed miR-21 contributes to tumorigenesis through compromising cell cycle progression and DNA damage-induced checkpoint function through the Cdc25a target gene (Wang et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Partly supportedcites Wang et al., 2009 sourceExperimental — accuracy not yet measured
The Results report targeted miR-21 deletion in RKO and DLD1 cells, and the Discussion links miR-21, Cdc25A, cell-cycle progression, and checkpoint activation. However, the Discussion describes a contribution to tumorigenesis as a possibility, not a demonstrated outcome; the claim's “revealed” overstates that conclusion. (LLM, conf=0.88)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“As well, epidermal growth factor receptor (EGFR) and HER2/neu signaling positively regulates miR-21 expression in human lung and breast carcinoma cell lines, respectively (Huang et al., 2009; Seike et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Supportedcites Huang et al., 2009 source
The paired citations and “respectively” attribute the HER2/neu finding in breast carcinoma cells to Huang et al. In “Ectopic Expression of HER2/neu Induces miR-21 Upregulation” (Fig. 1A; page not provided), the paper reports that HER2/neu expression increased miR-21 in a human breast cancer cell line. The EGFR finding in lung cells is not attributed to this source. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites Seike et al., 2009 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Zhang et al. showed in a human gastric cancer cell line that forced over-expression of miR-21 enhanced tumor proliferation and invasion”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Supportedcites Zhang et al., 2008 source
In the Results sections on proliferation and invasion (page numbers not provided), the paper reports that transfecting AGS human gastric cancer cells with a miR-21 expression construct significantly increased proliferation and strengthened invasion. This matches the claim about forced over-expression in a human gastric cancer cell line. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SPRY2, in turn, negatively regulates Ras/MEK/ERK signaling and is a tumor suppressor in NSCLC in both mice (Minowada and Miller, 2004; Minowada and Miller, 2009; Shaw et al., 2007) and humans (Sutterluty et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Minowada and Miller, 2004 source
- Partly supportedcites Minowada and Miller, 2009 sourceExperimental — accuracy not yet measured
The study summary and Discussion (page unavailable) report fewer and smaller urethane-induced lung tumors in mice overexpressing Sprouty 2, supporting a tumor-suppressive effect in that mouse model. The Discussion says the findings are consistent with antagonism of Ras signaling, but the mechanism remains unclear; this paper does not demonstrate inhibition of MEK/ERK signaling. The citing sentence attributes the human NSCLC portion to a separate citation, not to this paper. (LLM, conf=0.83)
- Supportedcites Shaw et al., 2007 source
The Negative feedback signaling in development section reports that Spry-2 inhibits MAPK activation in K-ras G12D mouse lungs. The tumor-suppression section concludes that Spry-2 limits K-ras-driven mouse lung tumor development; a correction in Additional information says its revised results do not change that conclusion. The citing sentence attributes the human finding to Sutterluty et al., not to this paper. (LLM, conf=0.90)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“All tumors from the survival cohort were analyzed on H&E sections and categorized as hyperplasia, atypical adenomatous hyperplasia, adenoma, adenoma with typia, and adenocarcinoma according to the Mouse Models of Human Cancer Consortium recommendations.(Nikitin et al., 2004)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > EXPERIMENTAL PROCEDURES > Tumor Grading
What the sources say
- Partly supportedcites Nikitin et al., 2004 sourceExperimental — accuracy not yet measured
The Development of Recommendations section says the consortium prepared and reviewed H&E-stained sections, and the classification defines hyperplasia, atypical adenomatous hyperplasia, adenoma, and adenocarcinoma. The cited paper does not identify “adenoma with typia” as a recommended category. The survival-cohort analysis describes the citing authors’ own work, not an analysis reported by Nikitin et al. (LLM, conf=0.85)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“knock-down of miR-21 resulted in a marked reduction in proliferation and increase in apoptosis (Zhang et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Supportedcites Zhang et al., 2008 source
The Abstract states that inhibiting miR-21 in AGS human gastric cancer cells significantly reduced proliferation and increased apoptosis. The ‘miR-21 Increases Cell Proliferation and Inhibits Cell Apoptosis’ section reports both effects after transfection with an anti-miR-21 inhibitor. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Methods have been developed to manipulate miRNA function pharmacologically, facilitating the development of new cancer therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Partly supportedcites Hutvagner et al., 2004 sourceExperimental — accuracy not yet measured
The Results and Discussion report that 2′-O-methyl oligonucleotides inhibit specific miRNAs and can be used to study their function in C. elegans. The paper presents them as a research tool; it does not establish that they facilitate new cancer therapeutic strategies. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites Krutzfeldt et al., 2005 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“RECK, Cdc25a, Map2k3, NfiB, Trp63 and Ski have been shown to be miR-21 target genes in vitro, but only RECK showed decreased protein levels in the CAG-miR-21;K-rasLA2 tumors (Figure S3A).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR21−/−;K-rasLA2 mice all develop lung tumors, but show an increased incidence of thymic lymphoma (Figure 2F).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Caspase 3 and K-ras do not contain miR-21 sites in their 3′ UTR and the 3′ UTR luciferase reporter activity is not suppressed by miR-21 (Figure 3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The decrease in Spry1, Spry2, and Btg2 in CAG-miR-21;K-rasLA2 tumors correlates with increased Ras pathway activity, shown by increased ERK phosphorylation (Figure 4C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show miR-21 dependent repression of the mouse Apaf1 3′ UTR reporter; however, the miR-21 site in the human APAF1 3′ UTR is conserved in primates but not conserved in the mouse.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“adult male CAG-miR-21 mice showed no signs of heart failure compared to littermate controls (Figure S1E)(van Rooij et al., 2006; van Rooij et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Apaf1, Pdcd4, Faslg, and RhoB were validated as direct miR-21 target genes by luciferase reporter assays; however, caspase 3 was not directly regulated by miR-21 (Figure 3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 suppresses apoptosis by targeting proapoptotic genes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 over-expression increased the incidence of all tumor grades without increasing the rate of conversion to adenocarcinoma, suggesting that miR-21 participates in tumor promotion rather than progression and metastasis in this model (Figure 1J and 1K).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Unlike K-rasLA1;p53−/− compound mutant mice (Johnson et al., 2001), we did not observe an increased tumor spectrum or increased metastasis in the CAG-miR-21;K-rasLA2 mutant mice.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although miR-21 function has been studied in vitro using cancer cell lines, the role of miR-21 in tumor development in vivo is unknown.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A large scale survey to determine the miRNA signature of 540 tumor samples including lung, breast, stomach, prostate, colon, and pancreatic tumors and their respective normal adjacent tissue revealed miR-21 was the only miRNA up-regulated in all these tumors (Volinia et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Volinia et al., 2006 source
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Further miRNA profiling in tumor samples and cancer cell lines show increased miR-21 expression in glioblastoma (Chan et al., 2005; Ciafre et al., 2005), head and neck carcinomas (Tran et al., 2007), ovarian cancer (Iorio et al., 2007), B-cell lymphoma (Lawrie et al., 2007), hepatocellular (Meng et al., 2007), and cervical carcinoma (Lui et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“CAG-miR-21 transgenic mice were viable, fertile and born in expected Mendelian ratios.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Knock-down of miR-21 in the metastatic breast cancer MD-MBA-231 cells reduced invasion and metastasis (Zhu et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Zhu et al., 2008 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Homozygous miR-21 knock-out mice are viable, fertile, and born in expected Mendelian ratios without any gross phenotypic differences compared to wild type or heterozygous littermates, and without a cardiac phenotype (D.P., E.V.R. and E.N.O., manuscript in preparation).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses Ras-driven transformation In vitro
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Rests on an assumption: The miR-21 knockout mice do not have compensatory molecular changes that confound the interpretation of tumorigenesis experiments.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data illustrate that miR-21 over-expression decreases the protein expression of four miR-21 target genes that are involved in apoptosis thus promoting survival.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 suppresses apoptosis by targeting proapoptotic genes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
In the paper
“miR-21 expression was induced by AP-1 in response to Ras activation, and miR-21 mediated Ras-dependent downregulation of Pdcd4 (Talotta et al., 2009)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Not checked — no full text of the sourcecites Talotta et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“Knockdown of miR-21 in cultured glioblastoma cells activates caspases leading to apoptotic cell death, suggesting miR-21 is an anti-apoptotic factor (Chan et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Chan et al., 2005 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“K-rasLA2 mice develop multi-focal lung tumors with 100% penetrance, and less frequently develop thymic lymphomas and skin papillomas (Johnson et al., 2001).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
What the sources say
- Not checked — no full text of the sourcecites Johnson et al., 2001 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data suggest that miR-21 over-expression in human tumors does not simply reflect cancer pathology, but instead enhances aspects of the pathology of NSCLC.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
In the paper
“Previously, an autoregulatory loop connecting miR-21 and Ras activation through AP-1 was illustrated in a rat thyroid cell system (Talotta et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Not checked — no full text of the sourcecites Talotta et al., 2009 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data show that miR-21 over-expression decreases the protein expression of four miR-21 target genes that are tumor suppressors and negative regulators of the Ras/MEK/ERK pathway resulting in a concomitant increased ERK activity.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
In the paper
“In breast cancer MCF-7 cells, miR-21 knock-down results in suppression of cell growth in vitro and tumor growth in xenografts (Si et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not matchedcites Si et al., 2007
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All mice used in these studies were of mixed genetic backgrounds and all comparisons were performed on littermate controls.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > EXPERIMENTAL PROCEDURES > Mouse Strains
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“PDCD4 is a pro-apoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2007; Bitomsky et al., 2008; Frankel et al., 2007; Lu et al., 2008; Zhang et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“In laryngeal carcinoma, miR-21 targets BTG2 (Liu et al., 2009), a p53 target gene, recently shown to suppress oncogenic Ras activity by reducing the GTP bound, active state (Buganim et al., 2010).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Knock-down of miR-21 in glioblastoma cell lines triggers the activation of caspases and increases apoptosis (Chan et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Chan et al., 2005 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“RhoB promotes growth inhibition and induces apoptosis in cancer cells (Kim et al., 2009)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Kim et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the reductions in protein levels of individual miR-21 targets appear modest with miR-21 over-expression, collectively this diminution of tumor suppressor activity allows for more robust tumor formation through relieving multiple nodes of inhibition of the Ras/MEK/ERK pathway, thus facilitating tumor proliferation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that Ras activation increases miR-21 expression and in turn decreasing the expression of Spry2.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“miR-21 modulates several components critical to NSCLC pathogenesis through both relieving antagonism of the Ras pathway and reducing apoptotic effectors (Figure 7).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
In the paper
“RhoB expression is down-regulated in human NSCLC suggesting a role as a tumor suppressor gene (Sato et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Sato et al., 2007 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Relieving miR-21 inhibition of pro-apoptotic genes could provide a means to augment the effect of current chemotherapy.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Rests on an assumption: Apaf1, Faslg, Pdcd4 and RhoB promote apoptosis.
In the paper
“MiR-21 targets SPRY2 in cardiomyocytes and SW480 colon cancer cells, enhancing cell migration (Sayed et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Sayed et al., 2008 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results show that miR-21 expression modulates tumor number, incidence and size in a mouse lung cancer model initiated by oncogenic K-rasG12D, consistent with miR-21 functioning as a tumor promoter.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
In the paper
“Pdcd4 functions both as an inducer of apoptosis and a suppressor of AP-1 activity (Hwang et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Hwang et al., 2007 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Loss of PDCD4 expression in human lung cancer correlates with higher grade and disease stage (Chen et al., 2003).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Chen et al., 2003 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
“To explore the role of miR-21 in the pathogenesis of NSCLC, we utilized the K-rasLA2 murine lung cancer model, which harbors a targeted, latent K-ras G12D allele that is activated by two distinct recombination events (Johnson et al., 2001).”
The paper relies on this without support.
The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
“which globally over-expressed miR-21 4–6 fold over normal levels of expression (Figure S1B–D).”
The paper relies on this without support.
The miR-21 knockout mice do not have compensatory molecular changes that confound the interpretation of tumorigenesis experiments.
“Homozygous miR-21 knock-out mice are viable, fertile, and born in expected Mendelian ratios without any gross phenotypic differences compared to wild type or heterozygous littermates, and without a cardiac phenotype (D.P., E.V.R. and E.N.O., manuscript in preparation).”
The paper relies on this without support.
The antibodies used in Western blots specifically detect the intended target proteins.
“We isolated individual tumors from mice, made whole tumor lysates, and performed Western blots for putative miR-21 targets to address the effect of miR-21 expression on the protein levels of the miR-21 target genes in vivo within lung tumors.”
The paper relies on this without support.
The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
“Reporter assays in COS cells revealed miR-21 dependent repression of 13 of the 24 3′UTRs”
The paper relies on this without support.
MicroRNAs are small non-coding RNAs that are commonly dysregulated in human malignancies and play a substantial role in the pathogenesis and survival of many cancers.
“MicroRNAs are small non-coding RNAs that are commonly dysregulated in human malignancies and play a substantial role in the pathogenesis and survival of many cancers.”
The paper relies on this without support.
MiR-21 is over-expressed in the majority of human malignancies including non-small cell lung cancer (NSCLC).
“MiR-21 is over-expressed in the majority of human malignancies including non-small cell lung cancer (NSCLC).”
The paper relies on this without support.
It is not clear whether miR-21 determines important aspects of lung cancer pathogenesis or is instead simply a marker for advanced disease.
“However, it is not clear whether miR-21 determines important aspects of lung cancer pathogenesis or is instead simply a marker for advanced disease.”
The paper relies on this without support.
Spry1, Spry2, Btg2, and Pdcd4 act as negative regulators of the Ras/MEK/ERK pathway.
“which act as negative regulators of the Ras/MEK/ERK pathway”
The paper relies on this without support.
Apaf1, Faslg, Pdcd4 and RhoB promote apoptosis.
“which promote apoptosis”
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855 · cited 2×
“Expression of approximately 30% of human proteins appears to be regulated by miRNAs (Lewis et al., 2005).”
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1997 · Cited by 7,668 · cited 2×
“…including non-small-cell lung cancer (NSCLC) (Volinia et al., 2006), and are predictive of tumor classification, prognosis, and response to therapy (Calin and Croce, 2006). miRNA expression patterns are remarkably reliable markers of cancers; in some cases, they have even proven more reliable than…”
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884 · cited 4×
“MicroRNAs are evolutionarily conserved, endogenous, nonprotein-coding, 20–23 nucleotide single-stranded RNAs that negatively regulate gene expression in a sequence-specific manner (Cho, 2007; Esquela-Kerscher and Slack, 2006; Voorhoeve and Agami, 2007).”
InfluentialA microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697 · cited 4×
“A large-scale survey to determine the miRNA signature of 540 tumor samples—including lung, breast, stomach, prostate, colon, and pancreatic tumors and their respective normal adjacent tissue—revealed miR-21 was the only miRNA upregulated in all these tumors (Volinia et al., 2006).”
InfluentialCombinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603 · cited 2×
“, 2007), and PicTar (Krek et al., 2005).”
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 2×
“Methods have been developed to manipulate miRNA function pharmacologically, facilitating the development of new cancer therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al., 2005).”
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766 · cited 2×
“Can miR-21 Targets Multiple Tumor Suppressor Genes To identify miR-21 effectors responsible for phenotypes observed, we utilized two algorithms that predict the mRNA targets of miRNAs, TargetScan (Grimson et al., 2007), and PicTar (Krek et al.”
The impact of microRNAs on protein output
Baek, D., Villén, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008) · Nature · doi:10.1038/nature07242 · Cited by 3,592 · cited 2×
“Through interactions with 30 UTRs, miRNAs can modulate the expression of many genes simultaneously, often regulating individual signaling pathways at multiple levels (Baek et al., 2008; Selbach et al., 2008).”
Widespread changes in protein synthesis induced by microRNAs
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008) · Nature · doi:10.1038/nature07228 · Cited by 3,429 · cited 2×
“Through interactions with 30 UTRs, miRNAs can modulate the expression of many genes simultaneously, often regulating individual signaling pathways at multiple levels (Baek et al., 2008; Selbach et al., 2008).”
Flagged first, then by citations
4 of the 74 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 625
Biallelic Dicer1 Loss Mediated by aP2-Cre Drives Angiosarcoma
Hanna, J. A., Drummond, C. J., Garcia, M. R., Go, J. C., Finkelstein, D., Rehg, J. E., & Hatley, M. E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1262 · Cited by 20
“IHC and mRNA in situ hybridization Histology and IHC performed following standard protocols (19) using antibodies detailed in Supplementary Table S2.”
MethodSelf-citationEfficient NMR Screening Approach to Discover Small Molecule Fragments Binding Structured RNA
Shortridge, M. D., & Varani, G. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00109 · Cited by 28
MicroRNA, epigenetic machinery and lung cancer
Kumar, R., & Xi, Y. (2011) · Thoracic Cancer · doi:10.1111/j.1759-7714.2011.00043.x · Cited by 20
MicroRNAs are involved in the toxicity of microcystins
Ma, J., & Li, X. (2016) · Toxin Reviews · doi:10.1080/15569543.2016.1258713 · Cited by 20
“MIR21 has been found to function as an oncomiR in cultured gliomas cells (Silber et al., 2009) and frequently over expressed in a variety of cancers (Hatley et al., 2010; Liu et al., 2011), suggesting that mir21 may be involved in zebrafish MCshepatotoxicity.”
BackgroundChu, N. J., Anders, R. A., Fertig, E. J., Cao, M., Hopkins, A. C., Keenan, B. P., Popović, A., Armstrong, T. D., Jaffee, E. M., & Zimmerman, J. W. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0053 · Cited by 20
“In addition, in a spontaneous transgenicmousemodel of KRAS-drivenNSCLC, overexpression of miR-21 enhanced tumorigenesis, while knockout of miR-21 reduced tumor formation in KRAS mice (42).”
BackgroundZhang, Y., Wang, Y., Xue, J., et al. (2021) · Bioengineered · doi:10.1080/21655979.2021.2009410 · Cited by 20
“One of the oncogenic miRNAs, miR-21-5p, is overexpressed in several cancer types and contributes to the growth, migration, and apoptosis of cancer cells [26,27].”
BackgroundRetractedMicroRNAs and polycystic kidney disease
Noureddine, L. A., Hajarnis, S. S., & Patel, V. (2013) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2013.10.001 · Cited by 20
The microRNA networks of TGFβ signaling in cancer
Sivadas, V. P., & Kannan, S. (2013) · Tumor Biology · doi:10.1007/s13277-013-1481-9 · Cited by 19
“[40] showed that in non-”
BackgroundNoncoding RNAs and their functional involvement in regulation of chronic myeloid leukemia
Wang, X., Chen, K., Guo, G., & Chen, J. (2015) · Briefings in Functional Genomics · doi:10.1093/bfgp/elv059 · Cited by 19
Yuan, H., Xin, S., Huang, Y., Bao, Y., Jiang, H., Zhou, L., Ren, X., Li, L., Wang, Q., & Zhang, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6605 · Cited by 21
“It has also been reported that miR-21 is able to regulate the Ras/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling pathway and therefore affect tumor formation (31).”
BackgroundJin, H., Jang, Y., Cheng, N., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1170-7 · Cited by 19
Schipper, J., Westerhuis, J. J., Beddows, I., Madaj, Z. B., Monsma, D. J., Hostetter, G. H., Kiupel, M., Conejo-Garcia, J. R., & Sempere, L. F. (2020) · International Journal of Cancer · doi:10.1002/ijc.33041 · Cited by 20
Zou, H., Chen, H., Liu, S., et al. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02350-y · Cited by 19
“Proliferation of tumors was evaluated with paraffin embedded tumor sections (4 μm) by immunohistochemistry using a monoclonal antibody against Ki67 (ab16667, Abcam, dilution 1:200), Vectastain ABC Kit (Vector Laboratories, Burlingame, CA, USA), and 3,3′-diaminobenzidine (DAB) substrate (Vector Laboratories) as describ…”
MethodMegiorni, F., Pizzuti, A., & Frati, L. (2011) · Pathology Research International · doi:10.4061/2011/780652 · Cited by 19
MicroRNA-873 inhibits colorectal cancer metastasis by targeting ELK1 and STRN4
Fan, C., Lin, B., Huang, Z., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24115 · Cited by 19
“Therefore, we speculated that miR-873 may exert its tumor-suppressive role by affecting the ERK-CyclinD1 axis which is one of the most essential pathways that control cell proliferation [19].”
BackgroundMicroRNAs and Polycystic Kidney Disease
Hajarnis, S. S., Lakhia, R., & Patel, V. (2015) · Codon Publications eBooks · doi:10.15586/codon.pkd.2015.ch13 · Cited by 20
Ibrahim, S., Johnson, M., Stephens, C. H., Xu, J., Moore, R., Mariani, A., Contreras, C., Syed, F., Mirmira, R. G., Anderson, R. M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101289 · Cited by 18
“Tg(bmiR-21) mice Tg(CAG-Z-miR-21-EGFP) [31] mice (backcrossed on a C57BL6/J background for >10 generations) were crossed with Ins1tm1(CreERT2)Thor [32] mice to generate Tg(bmiR-21)mice.”
MethodRegulation of microRNA ‐21 expression by natural products in cancer
Shakeri, A., Ghanbari, M., Tasbandi, A., & Sahebkar, A. (2021) · Phytotherapy Research · doi:10.1002/ptr.7069 · Cited by 19
“In non-small cell lung cancer (NSCLC), miR-21 stimulates oncogenic K-ras and regulates carcinogenesis by targeting Spry2, PDCD4, and BTG2, a tumor suppressor gene (Hatley et al., 2010).”
BackgroundChu, D., Li, P., Li, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14150 · Cited by 18
“Postmortem examination included weight measurement, and the tumors were analyzed for circ_0058357, miR-361-3p, ABCC1 and MMP9 expression levels by qRT-PCR and western blot as above and immunohistochemistry assay with antibodies against ABCC1 (ab260038, Abcam) and MMP9 (MA5-15886, Invitrogen), as described elsewhere.(2…”
MethodMutual interaction between BCL6 and miRNAs contributing to the pathogenesis of various cancers
Wei, Z., Gao, W., Wu, Y., Ni, B., & Tian, Y. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1322-y · Cited by 18
MicroRNA-Based Biomarkers in Lung Cancer: Recent Advances and Potential Applications
Shanehbandi, D., Asadi, M., Seyedrezazadeh, E., et al. (2022) · Current Molecular Medicine · doi:10.2174/2772432817666220520085719 · Cited by 17
The RAS oncogene in brain tumors and the involvement of let-7 microRNA
Messina, S. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09439-z · Cited by 22
“…of the RAS-ERK pathway (e.g., let-7 targets HRAS , NRAS and KRAS ) [1, 33], (ii) critical proteins that regulate the pathway and are required for proper spatial and temporal control of RAS-ERK signalling [29, 34, 35], and (iii) upstream drivers and downstream effector/regulator molecules [36, 37].”
BackgroundFu, B., Song, P. K., Lü, M., et al. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.10.002 · Cited by 17
The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma
Robinson, S. M., Fan, L. Y.-N., White, S. A., Charnley, R., & Mann, J. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.03.009 · Cited by 17
Choi, Y. W., Park, T. J., Kim, H. S., & Lim, I. K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.114 · Cited by 16
NMR Characterization of an Oligonucleotide Model of the MiR-21 Pre-Element
Chirayil, S., Wu, Q., Amezcua, C. A., & Luebke, K. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108231 · Cited by 18
“MiRNA-targeting antisense agents, called antagomirs, directed to miR-21 stimulate apoptosis or increased sensitivity to pro-apoptotic drugs in tumor cells [33,34], and genetic deletion of miR-21 in a mouse model of non-small cell lung cancer protects against tumor formation [35].”
BackgroundMicroRNA-Mediated Regulation of HMGB1 in Human Hepatocellular Carcinoma
Yan, J., Ying, S., & Cai, X. (2018) · BioMed Research International · doi:10.1155/2018/2754941 · Cited by 16
“In contrast to the miRNAs described above, miR-21 is frequently overexpressed in different malignant tumor cell lines and tissues, such as glioblastoma [86], breast cancer [87, 88], myeloma [89], colon cancer [90], prostate cancer [91], B-cell lymphoma [92], and lung cancer [93].”
ResultBalatti, V., Oghumu, S., Bottoni, A., Maharry, K. S., Cascione, L., Fadda, P., Parwani, A. V., Croce, C. M., & Iwenofu, O. H. (2018) · Head and Neck Pathology · doi:10.1007/s12105-018-0971-x · Cited by 16
Li, M.-Y., Liu, Y., Liu, L.-Z., Kong, A. W. Y., Zhao, Z., Wu, B., Long, X., Wu, J., Ng, C. S. H., Wan, I. Y. P., et al. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1300-4 · Cited by 17
“down-regulation of Pdcd4, Spry1, Spry2, and Btg2 [26], we assessed the role of miR-21 in the NNK-mediated RAS/ERK/ AP1 signaling pathway.”
Cheng, Y., Feng, Y., Zhao, J., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202422375 · Cited by 15
Petkova, V., Marinova, D., Kyurkchiyan, S. G., Stancheva, G. S., Mekov, E., Kachakova, D., Slavova, Y. G., Kostadinov, D., Mitev, V., & Kaneva, R. P. (2022) · Medicine · doi:10.1097/md.0000000000030027 · Cited by 16
A cellular regulator of the niche: telocyte
Babadag, S., & Çelebi‐Saltik, B. (2022) · Tissue Barriers · doi:10.1080/21688370.2022.2131955 · Cited by 15
“139 Most studies supported that miR-21 is an oncogenic miRNA and regulates various cancer-associated downstream effectors.”
BackgroundThe pathological role of microRNAs and inflammation in colon carcinogenesis
Zhang, L., & Fan, X. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.06.013 · Cited by 15
Jang, J.-Y., Jeon, Y., Lee, C.-E., & KIM, C.-W. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1736 · Cited by 15
Barati, S., Yadegari, A., Shahmohammadi, M., Azami, F., Tahmasebi, F., Rouhani, M. R., Kazemi, S., & Asl, E. R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01884-5 · Cited by 21
Yi, S., Lu, D., Peng, W., Wang, T., Zhang, Y., & Lin, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096336 · Cited by 14
“MiRNAs play an important role in many biological processes, such as development [2,3], cell proliferation, differentiation and death [4,5,6,7], tumorigenesis [8,9], and inflammation [10,11], in addition to several diseases [12,13].”
BackgroundOverview of KRAS‐Driven Genetically Engineered Mouse Models of Non‐Small Cell Lung Cancer
Sheridan, C., & Downward, J. (2015) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1435s70 · Cited by 14
“Indeed, the requirement for the p110α subunit of PI3K, AKT1, BMI1, mir21, and FOXP3+ regulatory T cells in the development of Kras-driven lung cancer was demonstrated with the KrasLA2 model (Gupta et al., 2007; Dovey et al., 2008; Granville et al., 2009; Hatley et al., 2010; Hollander et al., 2011).”
BackgroundTherapeutic Potentials of Noncoding RNAs: Targeted Delivery of ncRNAs in Cancer Cells
Liu, Y., & Wang, J. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-1498-7_16 · Cited by 14
Gebrie, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268480 · Cited by 17
“is induced by microRNA-21 directly targeting RasA1 and enhancing the RAS/RAF/MEK/ERK signaling pathway [93, 94].”
BackgroundMiR-23b inhibits cell migration and invasion through targeting PDE7A in colon cancer cells.
Hao, L., & Yu, H. (2017) · PubMed · Cited by 13
Zheng, S., Liao, J., Sun, M., Liu, R., & Lv, J. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15103 · Cited by 13
“21 Our previous next-generation sequencing data showed that miR-21 was abundant in both ESCC cells and their corresponding exosomes.”
MethodMicroRNAs as Biomarkers for Clinical Features of Lung Cancer
Hubaux, R. (2012) · Journal of Postgenomics Drug & Biomarker Development · doi:10.4172/2153-0769.1000108 · Cited by 14
“This miRNA is up-regulated by activation of EGFR and RAS pathways, and it is implicated in lung tumorigenesis in never smokers with KRAS and EGFR activating mutations and amplifications [43, 44].”
BackgroundDu, T., Jia, J.-S., Lin, X., Xie, R., Li, J., Xiao, D., & Xu, K. (2013) · Biotechnology Letters · doi:10.1007/s10529-013-1327-y · Cited by 13
Yu, L., Liang, X., Wang, J., Ding, G., Tang, J., Xue, J., He, X. Q., Ge, J., Jin, X., Yang, Z., et al. (2023) · Genetics Research · doi:10.1155/2023/6782732 · Cited by 14
“It also reported MiR-21-5p promoted the occurrence of lung cancer by inhibiting the RAS/MEK/ERK pathway and inhibiting apoptosis [69].”
BackgroundHaigl, B., Vanas, V., Setinek, U., Hegedűs, B., Gsur, A., & Sutterlüty, H. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2272 · Cited by 13
“reports described that EGFR (29) and K-Ras mutations (30,31) can influence miR-21 levels in lung cancer-derived tissue.”
Modeling of miRNA and Drug Action in the EGFR Signaling Pathway
Li, J., Pandey, V., Keßler, T., Lehrach, H. R., & Wierling, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030140 · Cited by 13
“miRNAs that bind to a protein encoding mRNA with imperfect complementarity repress the mRNA translation, whereas miRNAs binding to the mRNA with perfect complementarity target it for destruction [12].”
BackgroundOno, M., Yamada, K., Avolio, F., Afzal, V., Bensaddek, D., & Lamond, A. I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138668 · Cited by 13
Extrachromosomal circular DNA and their roles in cancer progression
Zheng, S., Li, Y., Wang, L., Wei, Q., Wei, M., Yu, T., & Zhao, L. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101202 · Cited by 16
Zhang, X., Huang, X., Zhang, X., Lai, L., Zhu, B., Lin, P., Kang, Z., Yin, D., Tian, D., Chen, Z., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561081 · Cited by 13
Maftouh, M., Avan, A., Galvani, E., Peters, G. J., & Giovannetti, E. (2013) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2013007191 · Cited by 12
Identification of pathogenic genes associated with CKD: An integrated bioinformatics approach
Ahmed, M. M., Shafat, Z., Tazyeen, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.891055 · Cited by 12
“Reports have suggested that miRNAs are associated with the regulation of various biological processes, such as proliferation, cellular differentiation, and metabolism (Carrington and Ambros, 2003; Sua ́rez and Sessa, 2009; Hatley et al., 2010).”
BackgroundMicroRNAs and Lymph Node Metastatic Disease in Lung Cancer
Fazi, F., & Fontemaggi, G. (2011) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2011.11.001 · Cited by 12
miRNA miR-21 Is Largely Dispensable for Intrathymic T-Cell Development
Kunze‐Schumacher, H., Winter, S. J., Imelmann, E., & Krueger, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02497 · Cited by 13
“Furthermore, overexpression of miR-21 promoted non-small-cell lung cancer, whereas loss of miR-21 suppressed development of tumors (42, 43).”
BackgroundThe novel circ_0084904/miR-802/MAL2 axis promotes the development of cervical cancer
Chen, L., Li, H., Yao, D., et al. (2022) · Reproductive Biology · doi:10.1016/j.repbio.2021.100600 · Cited by 11
Luo, S., Meng, X., Xu, L., & Zhang, X. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05287 · Cited by 11
MicroRNA‐Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer
Sharma, S. B., & Ruppert, J. M. (2015) · Drug Development Research · doi:10.1002/ddr.21270 · Cited by 11
“1) [Meng et al., 2007; Hatley et al., 2010; Zawistowski et al., 2013; Sharma et al., 2014; Lin et al., 2015].”
BackgroundMicro RNA s are differentially deregulated in mammary malignant phyllodes tumour
Tsang, J. Y., Ni, Y., Ng, E. K. O., Shin, V. Y., Mak, K. F., Go, E. M. L., Tawasil, J., Chan, S., Ko, C., Kwong, A., et al. (2015) · Histopathology · doi:10.1111/his.12648 · Cited by 11
“and target regulators of the Raf-mitogen-activated protein kinase (MAPK) [sprouty 1 (Spry1)] as well as phosphatidyl inositol-3-kinase (PI3K) pathways (PTEN).(12,18,21,22) Recently, high expression of miR21 in malignant PTs was reported.”
BackgroundNagy, Z., & Igaz, P. (2015) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-0955-9_1 · Cited by 12
Marzulli, M., Mazzacurati, L., Zhang, M., Goins, W. F., Hatley, M. E., Glorioso, J. C., & Cohen, J. B. (2018) · Journal of Gene Therapy · doi:10.13188/2381-3326.1000007 · Cited by 11
“Figure 6: Virus production by wild-type and miR-21 knock-out MEFs.”
BackgroundMethodInfluentialSelf-citationA novel circ_0099999/miR-330-5p/FSCN1 ceRNA crosstalk in pancreatic cancer
Wang, Y., Zhang, F., Wu, D., Wang, Q., Nie, L., & Yu, J. (2021) · Autoimmunity · doi:10.1080/08916934.2021.1963958 · Cited by 11
“Tumour tissues were processed for proliferation analysis by immunohistochemistry as reported [23], using an antibody specific to Ki67 (ab16667, Abcam, Cambridge, UK).”
MethodRole of Sprouty1 (Spry1) in the pathogenesis of atrial fibrosis
Qiao, G., Xia, D., Cheng, Z., et al. (2017) · Pathology - Research and Practice · doi:10.1016/j.prp.2017.04.021 · Cited by 11
Zheng, Y., Fei, Y., Wang, Z., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02280-5 · Cited by 11
Wang, X., Dong, M., Yang, J., Gong, Y., Huang, J., Yang, Q., Dong, H., & Zheng, J. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202408846 · Cited by 11
Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer
Fatima, S., Kumar, V., & Kumar, D. (2025) · Medical Oncology · doi:10.1007/s12032-025-02608-5 · Cited by 11
“By focusing on apoptosis-related factors including APAF-1, FASLG, PDCD4, and RHOB as well as factors that function as negative regulators of the RAS/MEK/ERK pathway such SPRY1, SPRY2, BTG2, and PDCD4, miR-21 overexpression encourages carcinogenesis [127].”
Karimipoor, M., Tafsiri, E., Darbouy, M., Shadmehr, M., & Cho, W. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.148673 · Cited by 10
Brücher, B. L. D. M., & Jamall, I. S. (2019) · 4open · doi:10.1051/fopen/2018996 · Cited by 10
Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy
Alti, D., Shanmukha, K. D., & Kalangi, S. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-021-07040-2 · Cited by 10
“It has been noticed that miR-21 is frequently upregulate in multiple cancers including k-Ras dependent lung tumors, where it attenuates the apoptosis by inhibiting Apaf-1 (key component of intrinsic pathway) and Fas-ligand [187].”
BackgroundNikolova, E., Georgiev, C., Laleva, L. N., et al. (2022) · Molecular Genetics and Genomics · doi:10.1007/s00438-021-01851-5 · Cited by 10
Emerging role of non-coding RNAs in the regulation of KRAS
Ghafouri‐Fard, S., Shirvani-Farsani, Z., Hussen, B. M., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02486-1 · Cited by 10
Khamis, T., Diab, A. E.-A. A., Zahra, M. H., Eldahmy, S., Al-Hameed, B. A. A., Abdelkhalek, A., Said, M. A., Abdellatif, H., Fericean, L. M., Bănățean-Dunea, I., et al. (2023) · Molecules · doi:10.3390/molecules28145543 · Cited by 11
Epigenetic regulation of RET receptor tyrosine kinase and non-coding RNAs in MTC
Joo, L. J. S., Zhao, J., Gild, M. L., Glover, A. R., & Sidhu, S. B. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.03.014 · Cited by 10
Patrick, D. M., Kauppinen, S., van Rooij, E., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46108 · Cited by 10
Self-citationThe Role of Non-Coding RNAs Involved in Nickel-Induced Lung Carcinogenic Mechanisms
Zhu, Y., Chen, Q. Y., Li, A. H., & Costa, M. (2019) · Inorganics · doi:10.3390/inorganics7070081 · Cited by 10
MicroRNA-124 rs531564 Polymorphism and Cancer Risk: A Meta-analysis
Li, W., Wang, Y., Gong, Y., et al. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.17.7905 · Cited by 9
“…apoptosis, differentiation, migration, metabolism, angiogenesis, signal transduction and tumor development and progression (Suarez and Sessa, 2009; Hatley et al., 2010; Krol et al., 2010; Kutanzi et al., 2011; Jansson and Lund, 2012; Kong et al., 2012; Pritchard et 1Medical Research Center, the…”
BackgroundVand‐Rajabpour, F., Savage, M., Belote, R. L., & Judson‐Torres, R. L. (2023) · Epigenomes · doi:10.3390/epigenomes7020009 · Cited by 9
Renna, F. J., González, C. D., & Vaccaro, M. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073758 · Cited by 9
Comparative mRNA and miRNA transcriptome analysis of a mouse model of IGFIR-driven lung cancer
Jones, R. A., Franks, S. E., & Moorehead, R. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206948 · Cited by 8
Vav1 accelerates Ras-driven lung cancer and modulates its tumor microenvironment.
Shalom, B., Farago, M., Salaymeh, Y., Sebban, S., Risling, M., Pikarsky, E., & Katzav, S. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110395 · Cited by 9
Wang, S., Wei, Z., Li, L., et al. (2024) · Microchimica Acta · doi:10.1007/s00604-024-06496-w · Cited by 8
Nor, W., Kwong, S. C., Fuzi, A. A. M., Said, N. A. B. M., Jamil, A. H. A., Lee, Y. Y., Lee, S. C., Lim, Y. A. L., & Chung, I. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5487 · Cited by 10
Meta-Analysis of Microarrays: Diagnostic value of microRNA-21 as a Biomarker for Lung Cancer
Meng, X., Chen, X., Zhao, Y., Jia, L., Tang, Y., & Li, D. (2015) · The International Journal of Biological Markers · doi:10.5301/jbm.5000153 · Cited by 8
“The upregulated miR-21 promotes tumorigenesis through inhibition of apoptosis and negative regulators of the Ras/MEK/ERK pathway (11).”
BackgroundImmunoreactivity of p53 and Ki-67 for Dysplastic Changes in Children with Eosinophilic Esophagitis
Denning, K. L., Al‐Subu, A. M., & Elitsur, Y. (2013) · Pediatric and Developmental Pathology · doi:10.2350/13-03-1306-oa.1 · Cited by 7
“The same microRNA-21 was also associated with the development of B-cell lymphoma and lung tumorigenesis, suggesting that EoE may be prone to cancer development [6,7].”
BackgroundZhu, Z., Zhang, H., Dong, X., Lin, M. S., & Yang, C. (2022) · Biosensors · doi:10.3390/bios12080557 · Cited by 10
Non-coding RNAs and exosomal non-coding RNAs in lung cancer: insights into their functions
Lv, X., Yang, L., Xie, Y., & Momeni, M. R. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1397788 · Cited by 8
Micro RNAs: an arguable appraisal in medicine
Voglova, K., Bezakova, J., & Herichová, I. (2016) · Endocrine Regulations · doi:10.1515/enr-2016-0013 · Cited by 9
“miR-21 can drive tumorigenesis by inhibiting negative regulators of Ras/MEK/ERK pathway and apoptosis (Hatley et al. 2010).”
Wang, D., Division, L. S., Hu, Z., & Hu, Z. (2011) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · doi:10.2172/1062099 · Cited by 9
Meta-analysis of the differentially expressed breast cancer-related microRNA expression profiles
Wu, J., Pan, L., Yang, T., & Wang, L. (2014) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2014.920782 · Cited by 7
“E-mail:wanglinmeillmm@hotmail.com and Ambros 2003; Hatley et al. 2010; Su á rez and Sessa 2009).”
BackgroundThe Role of Dysregulated MicroRNA Expression in Lung Cancer
Krutakova, M., Šarlinová, M., Matáková, T., Dzian, A., Hamžík, J., Pec, M., Javorkova, S., & Halasova, E. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_219 · Cited by 7
Is miR therapeutic targeting still a miRage?
Levantini, E. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4979 · Cited by 7
Wang, F., Zhong, S., Mao, C., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100722 · Cited by 7
“Immunohistochemistry (IHC) assays were implemented using standard methods [23] to measure PCNA abundance in tumor specimens using the antibody of PCNA (catalog number: ab29; Abcam).”
MethodA novel circ_0000654/ miR ‐375/ E2F3 ceRNA network in esophageal squamous cell carcinoma
Luo, C., Zhao, X., Wang, Y., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14550 · Cited by 7
“Paraffin-embedded tumor tissues were processed by immunohistochemistry analysis using anti-BCL-2 (Cat#PA5-20068), anti-c-Myc (Cat#PA5-85185), and anti-E2F3 (Cat#PA5-106407, all from Life Technologies) antibodies under standard protocols.(30)”
Methoddos Santos, P. R. M., Gomes, P. R. D. S., Romão, P., Maluf, F. C., Guimarães, V. R., Candido, P., Gonçalves, G. L., de Camargo, J. A., dos Santos, G. A., da Silva, I. A., et al. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10714-8 · Cited by 7
“…in many tumors, such as glioblastoma, head and neck cancer, ovary cancer, lymphomas, liver cancer, cervical cancer, breast cancer, and colorectal cancer (Asangani et al. 2008; Zhu et al. 2007; Kotzsch et al. 2005; Takenaka et al. 2004; Krichevsky and Gabriely 2009; Hatley et al. 2010).”
Genetically Engineered Mouse Models for Human Lung Cancer
Inoue, K., Fry, E. A., Maglic, D., & Zhu, S. (2013) · InTech eBooks · doi:10.5772/53721 · Cited by 8
“They showed that overexpression of miR-21 enhances lung tumorigenesis and that genetic deletion of miR-21 protects against tumor for‐ mation. miR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis (Hatley et al., 2010).”
BackgroundTang, S., Liu, B., Liu, M., Li, Z., Liu, J., Wang, H., Wang, J., Oh, Y.-T., Shen, L., & Wang, Y. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.03.012 · Cited by 7
Li, Y., Guo, R., Deng, C., et al. (2021) · Analytical Sciences · doi:10.2116/analsci.20p455 · Cited by 7
miRNA patterns in male LUSC patients - the 3-way mirror: Tissue, plasma and exosomes
Bica, C., Jurj, A. M., Haranguș, A., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101951 · Cited by 6
“In NSCLC, miR-21 promotes tumorigenesis by inhibiting negative regulators of the Ras/MEK/ERK signaling pathway [13] and stimulates cell growth and invasion by inhibiting tumor suppressor PTEN [14,15].”
BackgroundXing, J., Chai, H., Yang, L., et al. (2026) · ACS Sensors · doi:10.1021/acssensors.6c00154 · Cited by 6
Kalfeřt, D., Ludvíková, M., Pešta, M., Hakala, T., Dostálová, L., Grundmannova, H., Windrichová, J., Houfková, K., Knížková, T., Ludvík, J., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155319 · Cited by 6
Yan, Y., Xing, S., Liu, J. C., Yan, X., Guan, Y., Jiang, Z., Zhang, W., & Li, X. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110438 · Cited by 6
Zhang, J., Wang, F., Zhang, H., & Cao, M. (2021) · Bioengineered · doi:10.1080/21655979.2021.1989259 · Cited by 6
“Sections of paraffin-embedded tumors were used to measure the expression of NT5E and proliferating maker Ki67 by immunohistochemistry using NT5E (ab202122, Abcam) and Ki67 (ab15580, Abcam) antibodies, as reported elsewhere [29].”
Method
Metadata
- Authors
- Hatley, M. E., Patrick, D. M., Garcia, M. R., Richardson, J. A., Bassel-Duby, R., van Rooij, E., & Olson, E. N.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Olson, Eric N.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 18
- Issue
- 3
- Pages
- 282-293
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2971666
- OpenAlex
- W2169354377
- Semantic Scholar
- ea1aaa83b1883a1290ce31db3401b12568b668c7
- Cited by
- 626
- References
- 74
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 22 · 2022: 38 · 2021: 31 · 2020: 28 · 2019: 29 · 2018: 42 · 2017: 31 · 2016: 40 · 2015: 72 · 2014: 57 · 2013: 62 · 2012: 63
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion)
- PubMed Central (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL093039)
- National Cancer Institute
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD000850)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- miR-21, KRAS, lung carcinogenesis, non-small cell lung cancer, Ras/MEK/ERK pathway, apoptosis inhibition, transgenic mouse model, tumor suppressor microRNA
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Cell Transformation, Neoplastic, Humans, Lung Neoplasms, Mice, Nude, Mice, Transgenic, Genes, ras, Signal Transduction, MicroRNAs, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review